Florent Peyraud - Search Results

Year	Number of Results
2017	1
2020	2
2021	3
2022	3

1

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.

Peyraud F, Italiano A. Peyraud F, et al. Cancers (Basel). 2020 Jun 9;12(6):1502. doi: 10.3390/cancers12061502. Cancers (Basel). 2020. PMID: 32526888 Free PMC article. Review.

2

CSF-1R Inhibitor Development: Current Clinical Status.

Peyraud F, Cousin S, Italiano A. Peyraud F, et al. Curr Oncol Rep. 2017 Sep 5;19(11):70. doi: 10.1007/s11912-017-0634-1. Curr Oncol Rep. 2017. PMID: 28875266 Review.

3

Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.

Larroquette M, Peyraud F, Domblides C, Lefort F, Bernhard JC, Ravaud A, Gross-Goupil M. Larroquette M, et al. Among authors: peyraud f. Cancer Treat Rev. 2021 Jun;97:102207. doi: 10.1016/j.ctrv.2021.102207. Epub 2021 Apr 12. Cancer Treat Rev. 2021. PMID: 33906023 Review.

4

New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?

Peyraud F, Larroquette M, Ravaud A, Gross-Goupil M. Peyraud F, et al. Eur Urol. 2021 Sep;80(3):269-274. doi: 10.1016/j.eururo.2021.03.011. Epub 2021 Mar 31. Eur Urol. 2021. PMID: 33810923

5

Current management and future perspectives of penile cancer: An updated review.

Peyraud F, Allenet C, Gross-Goupil M, Domblides C, Lefort F, Daste A, Yacoub M, Haaser T, Ferretti L, Robert G, Ravaud A. Peyraud F, et al. Cancer Treat Rev. 2020 Nov;90:102087. doi: 10.1016/j.ctrv.2020.102087. Epub 2020 Aug 7. Cancer Treat Rev. 2020. PMID: 32799062 Review.

6

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.

Chevalier T, Daste A, Saada-Bouzid E, Loundou A, Peyraud F, Lambert T, Le Tourneau C, Peyrade F, Dupuis C, Alfonsi M, Fayette J, Reure J, Huguet F, Fakhry N, Toullec C, Salas S. Chevalier T, et al. Among authors: peyraud f. Cancer Med. 2021 Jun;10(12):3952-3963. doi: 10.1002/cam4.3953. Epub 2021 May 25. Cancer Med. 2021. PMID: 34080776 Free PMC article.

7

Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.

Blaye C, Boyer T, Peyraud F, Domblides C, Larmonier N. Blaye C, et al. Among authors: peyraud f. Front Immunol. 2022 Mar 3;13:838040. doi: 10.3389/fimmu.2022.838040. eCollection 2022. Front Immunol. 2022. PMID: 35309358 Free PMC article. Review.

8

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.

Peyraud F, Guegan JP, Bodet D, Cousin S, Bessede A, Italiano A. Peyraud F, et al. Front Immunol. 2022 Jan 31;13:807271. doi: 10.3389/fimmu.2022.807271. eCollection 2022. Front Immunol. 2022. PMID: 35173722 Free PMC article. Review.

9

VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.

Heraudet L, Galtier J, Favre S, Peyraud F, Cazaubiel T, Leroy H, Mottal N, Gros FX, Forcade E, Clément L, Dumas PY, Pigneux A, Leguay T. Heraudet L, et al. Among authors: peyraud f. Br J Haematol. 2022 May 7. doi: 10.1111/bjh.18218. Online ahead of print. Br J Haematol. 2022. PMID: 35524489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results